Research Papers:
DDX11-AS1 as potential therapy targets for human hepatocellular carcinoma
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1855 views | HTML 2179 views | ?
Abstract
Min Shi1,*, Xiao-Yu Zhang2,*, Heguo Yu3, Shi-Hao Xiang1, Ling Xu1, Jue Wei1, Qiong Wu1, Rongrong Jia1, Yu-Gang Wang1 and Xiao-Jie Lu4
1Department of Gastroenterology, Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2Department of General Surgery, Division of Gastrointestinal Surgery, The Affiliated Huai’an Hospital of Xuzhou Medical College and The Second People’s Hospital of Huai’an, Huai’an, Jiangsu, China
3NPFPC Key Laboratory of Contraceptives and Devices, Shanghai Institute of Planned Parenthood Research (SIPPR), Institutes of Reproduction and Development, Fudan University, Shanghai, China
4Department of General Surgery, Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
*Co-first authors
Correspondence to:
Yu-Gang Wang, email: [email protected]
Xiao-Jie Lu, email: [email protected]
Keywords: liver hepatocellular carcinoma, lncRNAs, DDX11-AS1
Received: February 13, 2017 Accepted: March 24, 2017 Published: April 25, 2017
ABSTRACT
Hepatocellular Carcinoma (HCC) is one of the most fatal cancers, whose incidence and death rates are still rising. Here, we report the identification of long non-coding RNAs (IncRNAs) that associated with HCC progression and metabolism based on the systematically analysis of large scale RNA-seq data from HCC patients. We identified seven lncRNAs with high confidence which were highly related with prognostic of HCC. Of note, three of them had quite different expression patterns between the control samples and the patients, and their critical roles in cancer progression were validated. We proposed that DDX11-AS1 play important role during HCC oncogenesis and may serve as potential therapy target for HCC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17409